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Summary
Donor criteria for liver grafts have been expanded because of organ shortage. Cur-
rently, no exact definitions for extended donor grafts have been established. The
aim of this study was to analyze the impact of donor-specific risk factors, inde-
pendent of recipient characteristics. In collaboration with Eurotransplant and
European Liver Transplant Register, solely donor-specific parameters were corre-
lated with 1-year survival following liver transplantation. Analyses of 4701 donors
between 2000 and 2005 resulted in the development of a nomogram to estimate
graft survival for available grafts. Predictions by nomogram were compared to
those by Donor Risk Index (DRI). In the multivariate analysis, cold ischemic time
(CIT), highest sodium, cause of donor death, c-glutamyl transferase (c-GT), and
donor sex (female) were statistically significant factors for 3 months; CIT, c-GT,
and cause of donor death for 12-month survival. The median DRI of this study
population was 1.45 (Q1: 1.17; Q3: 1.67). The agreement between the nomogram
and DRI was weak (kappa = 0.23). Several donor-specific risk factors were identi-
fied for early survival after liver transplantation. The provided nomogram will
support quick organ quality assessment. Nevertheless, this study showed the diffi-
culties of determining an exact definition of extended criteria donors.
Introduction
Outcome data after orthotopic liver transplantation have
continued to improve throughout the last decades. Never-
theless, transplant centers face the problem of rising num-
bers of patients on their waiting lists in contrast to a
limited number of stable available donor grafts [1–3]. Even
the use of living donors and donors after cardiac death
(DCD) could not overcome this imbalance [4]. Therefore,
transplant physicians and organ sharing networks try to
allocate, so-called, “extended criteria organs” very aggres-
sively to limit the number of patient deaths on the waiting
list. Several studies have demonstrated the safe use of such
extended criteria grafts with acceptable outcomes [5–7].
During the last decades, several studies have tried to
define parameters and cut-off values for extended criteria
organs, but there is still no general definition accepted
within the transplant community [8–10]. Several risk fac-
tors such as older donor age, prolonged cold ischemic time
(CIT) and hypotension, steatosis and high sodium values
have been widely accepted, although their impact differs
significantly in the reported studies [11–15].
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Because of this inhomogeneity, the aim of this study was
to identify solely donor-related risk factors for developing a
clinical evaluation tool for risk assessment of deceased liver
donors. This study reflects the current situation in Euro-
transplant (ET) and is based on merged data from ET data-
base and European Liver Transplant Registry (ELTR).
Materials and Methods
Data collection
Data were received for all liver transplantations performed
within the ET area between 2000 and 2005 from the ET
database, Leiden, Netherlands and ELTR, Paris, France
[2,3]. ET and ELTR databases were merged. Both registries
randomly undergo data review in a standardized manner.
The ELTR registry underlies a strict data audit by indepen-
dent members of participating countries. During the audits
in each center, 10% of liver transplant files are analyzed
and additionally evaluated by the ELTR data manager. In
ET donor, data undergo a plausibility check at the time of
data acquisition. In addition, the registry management ran-
domly cross-checks the documented donor data.
Median data completeness of the merged database was
69% (Q1: 64%, Q3: 100%). Almost 70% of risk factors
reached more than 80% data completeness.
Only deceased liver donors procured by transplant cen-
ters within the ET area were considered for analysis. DCD,
donors for split liver transplantation and recipients youn-
ger than 18 years were excluded from analysis.
This initial study revealed significantly poorer outcomes
for emergency transplantation and re-transplantation com-
pared with chronic liver failure. For the final donor risk fac-
tor analyses, it was decided to focus only on deceased
donors that were reported for first transplantation in the
standard allocation setting for chronic liver diseases.
Factors provided by the ET database included: cause of
brain death, donor age, sex, multiorgan donor Y/N, dura-
tion of stay in the intensive care unit, cardiac arrest/hypo-
tension Y/N, use of catecholamines Y/N, body mass index,
known insulin-depending diabetes mellitus and alcohol
abuse, activated partial thromboplastin time, sodium
(highest during intensive care unit stay and latest pre-
explantation), potassium, creatinine (highest and latest),
erythrocytes count, leukocytes count, C-reactive protein,
aspartate aminotransferase, alanine aminotransferase, total
bilirubin, c-glutamyl transferase (c-GT), lactate dehydroge-
nase, amylase, lipase, alanine phosphatase. Donor data are
stored anonymously in the ET database.
Factors provided by ELTR database included: indication
for transplantation [alcohol-induced, re-transplantation,
hepatocellular carcinoma (HCC), biliary, hepatitis C virus,
hepatitis B virus, metabolic, and others], sex mismatch,
CIT, cause of graft failure, follow-up time with patient- and
graft survival. In the case of multifactorial cirrhosis, only
the main underlying disease was considered for subgroup
classification resulting in eight groups of indication for
transplantation.
Outcome measures/statistical methods
Graft survival was defined as the time period from trans-
plantation to either recipient death or re-transplantation.
All donor-related factors were correlated with post-
transplant graft survival to define extended donor criteria.
Primary endpoints were survival or death/re-transplanta-
tion at 3 and 12 months of follow-up. Age was categorized
in 5-year steps (age 5), CIT in 15-min steps (CIT 15).
Statistical analyses were performed using SAS Version 9
(SAS Institute Inc., Cary, NC, USA) and R version 2.10
(http://www.r-project.org). Survival curves were generated
using Kaplan–Meier estimates and compared by log-rank
tests for univariate analysis with categorical variables.
Continuous variables were compared using hazard ratio
estimates and confidence intervals.
Stepwise Cox regression was used for multivariable mod-
eling, adjusted for overfit using 10-fold cross-validation, as
implemented in SAS and in R [16,17]. A predictive sum-
mary of the multivariate model was provided with a nomo-
gram. Predictive accuracy of the nomograms was assessed
using the area under the receiver operating characteristic
curve (AUC). An AUC of 1.0 indicates perfect discrimina-
tion, whereas an AUC of 0.5 indicates no discrimination by
the nomogram.
Comparison Donor Risk Index versus nomogram
The Donor Risk Index (DRI) described by Feng et al. was
calculated for each patient in our data set [12]. To facilitate
the comparison of DRI and the nomogram, we categorized
them into three groups based on the observed tertiles in
our data DRIs.
Ethics
The study protocol has been reviewed by the Institutional
Ethics Committee and has been performed in accordance
with the ethical standards laid down in the 2000 Declara-
tion of Helsinki as well as the Declaration of Istanbul 2008.
Results
A total of 6982 deceased liver donors were procured within
the ET area from 2000 to 2005. The 700 (10.0%) donors used
for split liver transplantation and the 149 (2.1%) organs
imported into the ET area were excluded from this analysis.
Therefore, the resulting initial study population consisted
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of 6133 deceased liver donors. In an initial analysis, emer-
gency transplantation (P = 0.01) and re-transplantation
(P < 0.01) were associated with significantly poorer 3- and
12-month survival rates compared with indications for
chronic liver failure. Therefore, these patients were excluded
for definite donor risk factor analyses, leaving 4701 patients.
Study population for risk factor analyses
Donor factors for the final study population are described
in detail in Table 1. Mean donor age was 42.8  17.4 years
(median 45 years), 44.1% of the donors were female.
Donor death was classified as cardiovascular (61.3%),
trauma (30.4%), suicide (4.0%), respiratory (3.6%), and
other reasons (0.7%).
Indications for transplantation were grouped as alcohol-
induced (24.3%), biliary disease (15.6%), malignancy
(16.5%), hepatitis C (15.7%), metabolic (7.8%), hepatitis B
(7.3%), and others (12.9%). No significant differences
regarding the graft survival owing to indications for trans-
plantation could be found.
Graft survival rates were 87.2% for 3 months and 81.2%
for 12 months. The re-transplantation rate was 10.7%.
Infection-related deaths (20.6%) were the main cause of
death in our study population, followed by, liver complica-
tions (17.3%; 5.3% as a result of primary nonfunction and
dysfunction), unclassified causes (13.7%), and cardio-
vascular-related deaths (8.4%). Multiorgan failure occurred
in 5.8% of patients and 6.5% of patients died intraopera-
tively. HCC recurrence caused only 3.4% of deaths within
the first year after transplantation.
Univariate analysis
In the univariate analysis age, cause of donor death, creati-
nine, c-GT, high sodium, and CIT were significant factors
for 3- and 12-month graft survival. In addition, donor sex
and the latest sodium were only significant to the 3-month
survival rate. Detailed data are shown in Table 2a. All other
investigated values did not show significance at any follow-
up time point.
Multivariate analysis
In the multivariate analysis CIT, high sodium, cause of
donor death, c-GT, and donor sex (female) were statisti-
cally significant for the 3-month graft survival rate. For the
12-month survival rate, only CIT, c-GT, and cause of
donor death remained statistically significant factors.
Detailed data are shown in Table 2b.
Nomogram
Based on the Cox proportional hazards regression model,
nomograms for 3 months (Fig. 1a) and 12 months
(Fig. 1b) were developed. All clinically relevant variables
served as a basis for this nomogram. The cross-validated
AUC was 0.570 (95% confidence interval: 0.543–0.596) for
the 3-month nomogram and 0.559 (0.536–0.582) for the
12-month nomogram. In Table 3, the use of the nomogram
is explained by an example for an optimal organ donor and
an extended criteria liver donor. Estimations of 3-month
survival are provided in Table 3a, 12-month survival in the
Table 3b.
Donor Risk Index
The mean DRI for this study population was 1.45 (Q1:
1.17; Q3: 1.67).
DRI versus Nomogram
The AUC for the DRI was 0.555 at 3 months and 0.557 at
1 year, values that are both lower than the cross-validated
Table 1. Donor and recipient data.
Factors
Study group
n = 4701
Gender
Male (%) 55.9
Female (%) 44.1
Age (years) 44 (30; 55)
BMI (kg/m2) 24 (22; 26)
Cause of death
Cardiovascular (%) 61.3
Trauma (%) 30.4
Suicide (%) 4.0
Respiratory (%) 3.6
Other (%) 0.7
CIT (h) 9.5 (7.6; 11.5)
Sodium latest (mmol/l) 146 (141; 152)
Sodium highest (mmol/l) 148 (143; 154)
Potassium (mmol/l) 4.0 (3.6; 4.4)
CRP (mg/dl) 1.7 (0.9; 2.9)
AST (U/l) 32 (19; 55)
ALT (U/l) 24 (14; 45)
c-GT (U/l) 23 (13; 51)
Bilirubin (mg/dl) 0.6 (0.4; 0.9)
PTT (s) 36 (30; 41)
Alkaline phosphatase 73 (52; 115)
Amylase (U/dl) 94 (46; 186)
Lipase (U/l) 105 (53; 197)
LDH (U/l) 300 (208; 453)
Creatinine (mg/dl) 0.8 (0.7; 1.1)
Data are presented as median and (lower; upper quartile).
CIT, cold ischemia time; CRP, C-reactive protein; AST, aspartate amino-
transferase; ALT, alanine aminotransferase; PTT, partial thromboplastin
time; LDH, lactate dehydrogenase.
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AUC of the nomogram. The agreement between the two
predictors was weak (kappa = 0.23) (Table 4a). Multiple
patients showed comparable outcomes, although they
were classified differentially according to DRI and the
nomogram (Table 4b). For example, 81% of the patients
who were low-risk DRI and intermediate by nomogram
were 1-year survivors and 78% of those who were high-risk
DRI and intermediate by nomogram survived the first year
after transplantation.
Discussion
Growing liver transplant waiting lists, combined with
increasing waiting list mortality rates, resulted in the
adoption of several different strategies to combat the issue
of organ shortage. The use of extended criteria donors
(ECD) has been promoted recently, as several studies have
shown acceptable long-term results with these organs
[8,9,18].
This collaborative study between ET and ELTR initially
aimed at creating a precise definition of extended criteria
deceased liver donors solely based on donor-related
factors, independent of medical recipient conditions. In
contrast to the currently established DRI by Feng et al.,
special donor conditions such as DCD and split liver
grafts with well-known significantly higher risk of organ
failure were excluded from analysis [13]. In addition,
recipients with acute liver failure or those that required
re-transplantation were excluded from the study popula-
tion (Group B) because significantly poorer graft survival
was found with these indications in this and previous
studies [19].
Furthermore, by limiting our analyses to 3 and
12 months after transplantation, we aimed at decreasing
the impact of recipient-related risk factors. In contrast to
the findings in Mells and Neuberger, our results show that
causes of post-transplant death change significantly with
longer follow-up time [20].
Although the focus of this study was the classical dis-
eased heart-beating liver donor, this manuscript highlights
the difficulties of defining ECD. Nevertheless, we were able
to demonstrate the interdependency of previously reported
Table 2. Univariate (A) and multivariate (B) analysis of risk factors for survival at 3 months and 12 months.
Factor
3 months 12 months
HR (CI) P-value HR (CI) P-value
A
Donor death 1.038 (1.016–1.060) 0.01 1.053 (1.028–1.078) 0.01
Age 5 1.022 (1.000–1.043) 0.048 1.032 (1.014–1.051) <0.01
Sex 1.167 (1.020–1.366) 0.02 1.021 (0.997–1.046) 0.08
BMI 1.000 (0.981–1.020) 0.97 1.004 (0.988–1.021) 0.61
CIT 15 1.010 (1.006–1.014) <0.01 1.009 (1.006–1.013) <0.01
Sodium 1.009 (1.001–1.017) 0.03 1.006 (0.999–1.013) 0.09
Potassium 1.019 (0.991–1.049) 0.19 1.022 (0.998–1.047) 0.07
Creatinine 1.032 (1.008–1.056) <0.01 1.033 (1.011–1.056) <0.01
AST/ALT 1.000 (0.999–1.001) 0.96 1.000 (0.999–1.001) 0.98
c-GT 1.001 (1.000–1.002) <0.01 1.001 (1.000–1.002) <0.01
Alkaline phosphatase 1.000 (0.999–1.001) 0.78 1.000 (0.999–1.001) 0.91
Amylase 1.000 (1.000–1.000) 0.40 1.000 (1.000–1.000) 0.29
Highest sodium 1.012 (1.004–1.019) <0.01 1.008 (1.001–1.015) 0.02
Highest creatinine 0.964 (0.876–1.062) 0.46 0.988 (0.920–1.061) 0.74
LDH 1.000 (1.000–1.000) 0.42 1.000 (1.000–1.000) 0.25
Bilirubin 1.006 (0.956–1.058) 0.82 0.992 (0.943–1.044) 0.77
B
CIT 15 1.010 (1.005–1.015) <0.01 1.009 (1.005–1.013) <0.01
c-GT 1.001 (1.000–1.002) 0.03 1.001 (1.000–1.002) 0.01
Donor death 1.242 (1.008–1.529) 0.04 1.323 (1.333–1.545) 0.02
Highest sodium 1.015 (1.002–1.028) 0.02 1.009 (0.998–1.021) 0.11
Sex 1.275 (1.023–1.589) 0.03 1.021 (0.997–1.046) 0.08
Age 5 1.016 (0.987–1.045) 0.26 1.019 (0.995–1.044) 0.12
Creatinine 0.937 (0.810–1.084) 0.38 0.998 (0.987–1.009) 0.71
Sodium 0.998 (0.986–1.010) 0.66 0.995 (0.891–1.112) 0.93
Age 5, age categorized in 5 year steps; ALT, alanine aminotransferase; AST, aspartate aminotransferase; c-GT, gamma glutamyl transferase; BMI, body
mass index; CIT, cold ischemia time; CIT 15, cold ischemia time categorized in 15 min steps; CRP, C-reactive protein; LDH, lactate dehydrogenase.
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donor risk factors in accordance with currently established
literature [18,21,22].
Donor age and cause of donor death
In this study population, donor age was only a predictor of
post-transplant survival in the univariate analysis without
revealing any cut-off value. The general increase in mean
donor age might be reflected in an alteration of the causes
of donor death, as well [1]. Currently, more than 60% of
organs are procured from donors who have died from
cardiovascular disease [23]. Our data reveal a statistically
significant negative effect of cardiovascular donor death for
3- and 12-month survival following transplantation. Never-
theless, the question has to be raised, if cardiovascular cause
of death should be considered as standard as it represents
more than 60% cases and trauma-related death a protective
factor?
Sex mismatch and donor sex
Female donors showed a negative impact on 3-month post-
transplantation survival, a phenomenon that can be
attributed to Alloimmunity mechanisms and hormonal
Figure 1 (a) Nomogram for 3-month survival estimation. Blue bars illustrate the use of the nomogram. The “optimal donor” of Table 3 serves as exam-
ple for 3-month survival estimation. (b) Nomogram for 12-month survival estimation. Each axis represents one of the significant variables of the multivari-
ate analysis. Variable-specific values have to be correlated (straight upward) with the top point axis. Finally, all points of each variable have to be added
and the total sum can be linked with the survival axis in the lowest row. Gamma, c-glutamyl transferase (U/l); ischemic time (h); highest NA, highest doc-
umented sodium during ICU stay (mmol/l). Cause of death: R, respiratory; C, cardiovascular; T, trauma; S, suicide; O, other. Sex: F, female; M, male.
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differences [24–28]. In liver transplantation, only few
elderly data are published about gender mismatch, compa-
rable with our data [29–31].
Cold ischemic time
Usually, more than 12 h of CIT correlated with poor
initial graft function or organ failure [13,32]. We could
not identify a cut-off value as described in previous
studies, but confirm a negative correlation for graft
survival with prolonged CIT [8,12,13,33]. Each hour
extension of CIT roughly corresponded to a 4% (abso-
lute) decrease in the probability of 1-year graft survival.
In cases involving long distance organ shipment owing
to Model for End-Stage Liver Disease (MELD) score
allocation, CIT may become increasingly more important
to the decision of donor acceptance, especially in case of
ECD. We are aware that the exact CIT is not always
predictable before organ allocation and organ harvesting.
Nevertheless, delays in transportation or prolonged dura-
tion of hepatectomy might be very rare events or
initially predictable.
Figure 1 Continued.
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c-glutamyl transferase
Evaluation of donor organs solely based on liver-specific
laboratory values is a controversial topic in medical
literature [11,34–37]. In our study population, only c-GT
was associated with increased graft failure in the multivari-
ate analysis for 3- and 12-month survival. c-GT might
reflect chronic organ damage more precisely than transam-
inases. Donor-related comorbidities such as cardiovascular
disease, diabetes type II, chronic kidney disease, or alcohol
abuse can also cause increased c-GT values [38,39]. Never-
theless, one limitation of our data was the missing correla-
tion of laboratory values with initial protocol biopsies of
grafts. These are not standard, and therefore, not routinely
reported to the registries in the ET area. Likewise, available
ultrasound exams are generally of limited quality and there-
fore not considered for analyses.
Sodium levels
Direct osmolar damage is responsible for hepatocellular
swelling and dysfunction [15]. In our study, cohort high
sodium value during the donor’s stay in the intensive care
unit was a significant factor for post-transplant outcome,
in contrast to the last available sodium value before pro-
curement. This supports our theory that short-term
changes in sodium values result in long lasting damage
within hepatocytes because of intracellular osmolarity
changes, even after aggressive correction of the donor
serum sodium level [40].
A further aspect of the determined risk factors is their rele-
vance at different points in time. In our study, female donor
sex and high values of sodium prior to transplantation were
only significant factors for 3-month survival rates and lost
significance when determining 12-month survival. Regard-
ing long-term survival, recipient and disease-related risk fac-
tors overpower the impact of donor-related risk factor.
Nomogram
Comparable to the correlation of the probability of death
on the waiting list by MELD score, the provided nomogram
might offer a tool to calculate the risk of graft failure based
solely on donor-related risk factors [41]. As described in
Methods section, each of the significant factors of the mul-
tivariate analysis is represented within the calculations.
Evaluation of a liver donor by the nomogram will reveal
interesting interactions between different donor variables,
highlighting the complexity of defining an extended criteria
liver donors. Examples for an optimal donor and an
extended criteria liver donor are provided in Table 3.
The bias that might result from this model selection is
offset using 10-folding cross-validation for model evalua-
tion. The resulting AUCs are comparable to those nomo-
grams that are used in predicting postresection survival in
common cancers and suggest a modest ability to determine
early deaths.
DRI versus Nomogram
In addition, the DRI was calculated for all donors and
correlated with outcome prediction based on the derived
Table 3. Manual for the use of the nomogram with an example of an “optimal” liver organ donor and an “extended criteria” liver donor.
Variable
Optimal Extended
Example value
3 months
axis points
12 months
axis points Example value
3 months
axis points
12 months
axis points
Sex Male 15 12 Female 0 0
Cause of death Trauma 40 27 CVA 25 0
Highest sodium 140 mmol/l 32 16 160 mmol/l 10 6
CIT 12 h 75 61 15 h 37 37
c-GT 25 U/l 41 30 100 U/l 25 15
Sum axis points 203 146 97 58
Estimated survival (%) 84 84 70 64
CVA, cerebrovascular accident; highest sodium, highest documented value during ICU stay; CIT, cold ischemia time.
Table 4. (A) Number of patients cross classified by DRI and Nomogram
and (B) percent of patients alive at 1 year.
Nomogram
low risk
Nomogram
intermediate
Nomogram
high risk
A
DRI low risk (%) 16 12 5
DRI intermediate (%) 13 13 8
DRI high risk (%) 4 8 21
B
DRI low risk (%) 86 81 79
DRI intermediate (%) 82 81 77
DRI high risk (%) 82 78 73
DRI, Donor Risk Index.
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nomogram. Contrasting our nomogram predictions with
DRI revealed that these tools are quite different and
agreement between the two is very poor. Although it is
possible that they contain complementary information, we
believe the differences in the underlying patient populations
on which they are based are more likely to be responsible. It
is of note that the nomogram had slightly better AUC than
the DRI, although both leave substantial room for improve-
ment, underscoring the difficulty of predicting outcomes
following transplantation or classifying donor quality. We
did not perform a statistical comparison of the two as the
nomogram was developed based on a different data set, and
therefore such a comparison would be inherently in favor of
the nomogram. Significant differences in graft quality
between United Network of Organ sharing and ET were
recently discussed by Braat and Blok when presenting their
Eurotransplant Donor Risk Index (ET-DRI) [42,43].
Nevertheless, the comparison of predicting tools like ET-
DRI, DRI and the nomogram supports our initial statement
on how difficult it is to define an extended criteria liver
donor.
Readers might raise the argument that this study has
some limitations as we have excluded established high-risk
settings like split liver grafts and DCD, acute liver failure,
and re-transplantation [13]. Rather, we are of the opinion to
define donor-related risk factors even more precisely as we
do not weaken the statistic power of our data because of
excluding these well-established high-risk settings [13,19].
In addition, this study may be criticized for not taking
into account recipient-related disease severity represented
by MELD score. As a rebuttal to this argument, we want to
point out once again that the focus of this study was set on
the definition of solely donor-related risk factors for early
graft failure in deceased heart-beating donors for first time
recipients with end-stage liver disease independent of their
disease severity. We are also of the opinion that including
recipient conditions would weaken the statistical power of
donor-related risk factors. Furthermore, the study popula-
tion was defined in the pre-MELD era.
Finally, all analyzed donor factors were generated from
finally procured and transplanted grafts. These grafts repre-
sent a preselected group of donors with at least a minimum
level of organ quality. Organs of obviously poor quality
were eliminated from use during the pretransplantation
evaluation process before organ procurement. This is also
reflected in a relatively low rate of primary nonfunction/
primary dysfunction rate of 5%.
In conclusion, several donor-related risk factors were
defined for early outcome following liver transplantation
(CIT, high sodium, cause of donor death, c-GT, and female
donor sex for the 3-month graft survival; CIT, c-GT, and
cause of donor death for the 12-month follow-up). In times
of organ shortage and for optimizing organ utilization, our
nomogram might provide a simple tool for organ quality
assessment based on survival estimation, consequently sup-
porting a more individualized organ allocation in the
future. Nevertheless, this study shows the difficulties of
developing a precise prediction tool for outcome after liver
transplantation based on organ quality.
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